(:EIDX)

Jan 26, 2021 08:30 am ET
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already...
Jan 19, 2021 04:01 pm ET
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio’s acquisition of all...
Jan 13, 2021 04:30 pm ET
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to...
Jan 05, 2021 10:26 am ET
ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 04, 2021 11:42 am ET
EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their fiduciary duties or violated the federal...
Jan 04, 2021 07:30 am ET
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger
BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio’s...
Dec 30, 2020 07:49 pm ET
Dec 30, 2020 10:04 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – CKH, WDR, NAV, EIDX
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: SEACOR Holdings Inc. (NYSE: CKH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Dec 28, 2020 07:20 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PRGX, STND, NK, EIDX, ARA
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 24, 2020 09:09 am ET
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers – STND, EIDX, ARA, RESI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Standard AVB Financial Corp. (NASDAQ: STND) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Dec 19, 2020 03:17 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - STND, EIDX, WTRE, ARA, CGIX
NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 16, 2020 12:14 pm ET
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, Dec. 16, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:
Dec 12, 2020 09:12 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm – CBMG, MVC, STND, EIDX
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Dec 11, 2020 07:52 pm ET
Dec 05, 2020 05:06 am ET
ALERT: Halper Sadeh LLP Encourages EIDX, WTRE, RESI, and XLNX Shareholders to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following mergers: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Dec 04, 2020 07:51 pm ET
Dec 04, 2020 10:48 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - PNM, ELY, TNAV, NAV, EIDX
NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Dec 02, 2020 12:03 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MCEP, EIDX, CCR, and TGC Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Mid-Con Energy Partners, LP (NASDAQ GS: MCEP) regarding possible breaches of fiduciary duties and other violations of law related to Mid-Con Energy’s agreement to be acquired by Contango...
Nov 25, 2020 10:31 pm ET
Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – STND, EIDX, WTRE, EV
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Standard AVB Financial Corp. (NASDAQ: STND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale...
Nov 23, 2020 07:31 pm ET
Nov 20, 2020 09:33 pm ET
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – GLIBA, EIDX, EV, PNM
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: GCI Liberty, Inc. (NASDAQ: GLIBA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...
Nov 19, 2020 06:36 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of CXO, CEIX, PNM, and EIDX Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Concho Resources Inc. (NYSE: CXO) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips....
Nov 13, 2020 10:34 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Investigations; Investors are Encouraged to Contact the Firm – STND, EIDX, WTRE, EV
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Standard AVB Financial Corp. (NASDAQ: STND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale...
Nov 13, 2020 12:30 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IPHI, EIDX, CEIX, and PNM Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Inphi Corporation (NASDAQ GS: IPHI) regarding possible breaches of fiduciary duties and other violations of law related to Inphi’s agreement to be acquired by Marvell Technology Group...
Nov 12, 2020 12:40 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - GLIBA, VRTU, PRCP, WPX, EIDX
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Nov 09, 2020 05:15 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigation of Eidos Therapeutics, Inc. Buyout
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos' agreement to be acquired by BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ GS: BBIO).  Under the terms of the agreement, Eidos' shareholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per share.
Nov 07, 2020 07:49 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – EIDX, WTRE, ARA, CIT
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...
Nov 05, 2020 07:30 am ET
BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today reported its...
Oct 31, 2020 06:57 pm ET
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - EIDX, RESI, PE, ARA
NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Oct 30, 2020 03:30 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Callaway Golf Company (NYSE: ELY), Eidos Therapeutics, Inc. (NASDAQ: EIDX), Inphi Corporation (NASDAQ: IPHI), and Watford Holdings Ltd. (NASDAQ:WTRE
Callaway Golf Company (NYSE: ELY) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ELY to Topgolf Entertainment Group. Under the terms of the merger agreement, Callaway will...
Oct 29, 2020 04:30 pm ET
Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company’s operations. “The completion of enrollment in our Phase 3 ATTRibute-CM...
Oct 26, 2020 01:36 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of CXO, BSTC, CIT, and EIDX Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Concho Resources Inc. (NYSE: CXO) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips....
Oct 20, 2020 03:12 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm - MYOK, EIDX, CBMG
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Oct 19, 2020 03:24 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of EIDX, ARA, MVC, and CGIX Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Eidos Therapeutics, Inc. (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma,...
Oct 15, 2020 12:06 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc. (NYSE: ARA), BMC Stock Holdings, Inc., Cellular Biomedicine Group, Inc., and Eidos Therapeutics, Inc.
American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a...
Oct 14, 2020 03:09 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Eidos Therapeutics, Inc. -EIDX
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Eidos Therapeutics, Inc. ("Eidos" or the "Company") (EIDX) relating to its proposed acquisition by BridgeBio Pharma, Inc. ("BridgeBio"). Under the terms of the agreement, Eidos' shareholders will receive 1.85 shares of BridgeBio common stock or $73.26 in cash per share.
Oct 14, 2020 01:14 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of EIDX, VRTU, CBMG, and CGIX Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Eidos Therapeutics, Inc. (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma, Inc....
Oct 09, 2020 06:23 pm ET
EIDOS MERGER INVESTIGTION ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Eidos Therapeutics, Inc. - EIDX
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ:...
Oct 09, 2020 02:38 pm ET
EIDOS THERAPEUTICS INVESTOR ALERT BY The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eidos Therapeutics, Inc. - EIDX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Eidos Therapeutics, Inc. (NasdaqGS: EIDX) to BridgeBio Pharma, Inc. (NasdaqGS: BBIO). Under the terms of the proposed transaction, shareholders of Eidos will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 09, 2020 11:19 am ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of EIDX, GLIBA, SUNW, and BMCH Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Eidos Therapeutics, Inc. (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma, Inc....
Oct 07, 2020 05:36 pm ET
EIDX INVESTIGATION – Shareholder Rights Firm Labaton Sucharow is Investigating Eidos Therapeutics (NASDAQ: EIDX) for Potential Securities Violations and Breach of Fiduciary Duty
Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ: EIDX).
Oct 07, 2020 08:56 am ET
EIDX INVESTIGATION – Shareholder Rights Firm Labaton Sucharow is Investigating Eidos Therapeutics (NASDAQ: EIDX) for Potential Securities Violations and Breach of Fiduciary Duty
Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ: EIDX).
Oct 05, 2020 09:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Eidos Therapeutics, Inc. Buyout
Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio...
Oct 05, 2020 05:10 pm ET
Eidos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Eidos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – EIDX
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Eidos Therapeutics, Inc. (NASDAQ: EIDX) to BridgeBio Pharma, Inc. is fair to Eidos shareholders. On behalf of Eidos shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Oct 05, 2020 01:46 pm ET
EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their fiduciary duties or violated the federal...
Oct 05, 2020 07:04 am ET
BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a company focused on genetic diseases, and Eidos Therapeutics, Inc. (Nasdaq: EIDX), a company focused on transthyretin (TTR) amyloidosis (ATTR), today announced they have entered into a definitive agreement...
Aug 07, 2020 04:30 pm ET
Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors
Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new...
Aug 06, 2020 04:30 pm ET
Eidos Therapeutics Reports Second Quarter 2020 Financial Results and Business Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the second quarter ended June 30, 2020 and provided an update on the company’s operations. “While the COVID-19 pandemic poses an unpredictable threat to our...
Jun 10, 2020 09:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eidos Therapeutics, Inc. - EIDX
Pomerantz LLP is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (NASDAQ: EIDX).   The investigation concerns whether Eidos and certain of its officers and/or directors have breached fiduciary...
May 08, 2020 04:30 pm ET
Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations. “We are living in unprecedented times as the impact of the...
Feb 26, 2020 04:30 pm ET
Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the company’s recent achievements. “2019 marked another year of significant...
Nov 16, 2019 05:30 pm ET
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO) and Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today presented positive data from the companies’ ongoing Open Label Extension (OLE) of the Phase 2 clinical trial studying AG10 in patients with...
Oct 31, 2019 04:30 pm ET
Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the company’s recent...
Oct 14, 2019 07:30 am ET
BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics
BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics (NASDAQ: EIDX), a clinical-stage biopharmaceutical company developing AG10 for the treatment of transthyretin amyloidosis (ATTR), to acquire the outstanding common stock of Eidos that BridgeBio does not already own (approximately 34% of Eidos’s outstanding shares).
Sep 30, 2019 07:00 am ET
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Break
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced that an interim analysis of its ongoing...
Sep 19, 2019 08:00 am ET
Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at 3:00 p.m. EDT in New York, NY. A live audio webcast of the presentation can be...
Sep 16, 2019 08:03 am ET
EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against Eidos Therapeutics, Inc. (NASDAQGS: EIDX) (“Eidos” or the “Company”).
Sep 12, 2019 06:50 pm ET
Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares
Eidos Therapeutics, Inc. (Nasdaq:EIDX) (“Eidos”) announced today that the Special Committee of its Board of Directors (the “Special Committee”) unanimously rejected the non-binding proposal dated August 8, 2019 (the “Proposal”) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (“BridgeBio”), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.
Sep 03, 2019 12:15 pm ET
Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDX
Kaskela Law LLC is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ: EIDX) on behalf of the company’s shareholders.  The investigation seeks to determine whether Eidos and/or the company’s officers and directors have violated the...
Aug 12, 2019 08:25 am ET
Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares
Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the “Company”) today confirmed that it has received a non-binding proposal dated August 8, 2019 (the “Proposal”) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (“BridgeBio”), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio. BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, approximately 66.6% of the outstanding shares of the Company’s common stock.
Aug 01, 2019 04:30 pm ET
Eidos Therapeutics Reports Second Quarter 2019 Financial Results
Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an update on the company’s recent achievements. “We remain focused on executing our Phase 3 program...
Jun 18, 2019 08:00 am ET
Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25th at 2:40 p.m. EDT in New York, NY. A live audio...
May 07, 2019 04:30 pm ET
Eidos Therapeutics Reports First Quarter 2019 Financial Results
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company’s recent achievements. “The initiation of our Phase 3 ATTRibute-CM study in the...
Apr 19, 2019 08:00 am ET
Eidos Therapeutics to Present at Two Upcoming Investor Conferences
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences. Class of 2018 Biotech IPOs Investor Day The company will present on Friday, April 26, 2019 at 3:30 p.m. ET. The...
Apr 15, 2019 08:30 am ET
Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on the company’s recent achievements. “2018 marked another year of significant...
Apr 05, 2019 03:40 pm ET
RM LAW Announces an Investigation of Eidos Therapeutics, Inc.
BERWYN, Pa., April 5, 2019 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Eidos Therapeutics, Inc. (NASDAQ: EIDX) ("Eidos Therapeutics" or the "Company") investors concerning the Company and its officers' possible violations of federal securities laws.
Apr 05, 2019 09:56 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or “the Company”) (NASDAQ:
Apr 01, 2019 09:54 pm ET
Bragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Eidos Therapeutics, Inc. (NASAQ: EIDX).  Our investigation concerns whether Eidos has violated the federal securities laws and/or engaged in other unlawful business practices....
Apr 01, 2019 08:59 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or “the Company”) (NASDAQ:
Apr 01, 2019 07:59 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. – EIDX
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Eidos Therapeutics, Inc. (NASDAQ:EIDX) resulting from allegations that Eidos may have issued materially misleading business information to the investing public.
Apr 01, 2019 06:34 pm ET
Eidos Therapeutics Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
Block & Leviton LLP (www.blockesq.com), one of the nation’s leading securities litigation firms representing investors nationwide, is investigating whether Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (NASDAQ: EIDX) and certain of its...
Mar 18, 2019 09:30 am ET
Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced the publication of its...
Mar 11, 2019 08:00 am ET
Eidos Therapeutics to Present at 31st Annual ROTH Conference
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the 31st Annual ROTH Conference on Monday, March 18th at 8:30 a.m. PDT in Orange County, CA. A live...
Feb 27, 2019 07:00 am ET
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). The design of the...
Feb 25, 2019 08:00 am ET
Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it will host an investor...
Feb 21, 2019 08:00 am ET
Eidos Therapeutics to Present at Two Upcoming Investor Conferences
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences. SVB Leerink Global Healthcare Conference The company will present on Thursday, February 28, 2019 at 11:00 a.m. ET....
Jan 02, 2019 08:00 am ET
Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th at 4:30 p.m. PST in San Francisco, CA. The presentation...
Dec 06, 2018 04:15 pm ET
Eidos Therapeutics Appoints William Lis to Board of Directors
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced the appointment of William Lis, to Eidos’ Board of...
Nov 21, 2018 08:15 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Okta, One Horizon Group, Vivopower International Plc, PetIQ, Quanterix, and Eidos Therapeutics — New Research Emphasizes Economic Gr
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), One Horizon Group, Inc. (NASDAQ:OHGI),...
Nov 14, 2018 08:00 am ET
Eidos Therapeutics to Present at Two Upcoming Investor Conferences
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present a company overview at two upcoming investor conferences. Piper Jaffray Healthcare Conference The company will give a corporate presentation on Wednesday,...
Nov 10, 2018 10:00 am ET
Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy
AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28 AG10 Significantly Raised Serum TTR Concentrations...
Nov 06, 2018 04:05 pm ET
Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today reported its financial results for the quarter ended...
Oct 29, 2018 08:00 am ET
Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will host a conference call and webcast to discuss the results of its Phase 2 clinical trial of AG10 in patients with transthyretin amyloidosis cardiomyopathy and...
Oct 26, 2018 08:00 am ET
Eidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin Amyloidosis
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), announced today that the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for the designation of Eidos’ product candidate, AG10, as...
Oct 05, 2018 09:10 am ET
Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking...
Oct 03, 2018 02:35 pm ET
FDA Grants Orphan Drug Designation to Eidos Therapeutics’ Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), announced today that the U.S. Food and...
Sep 25, 2018 08:00 am ET
Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease Oncology on Tuesday, October 2, 2018 at 3:30 p.m. ET. The conference will...
Sep 17, 2018 08:00 am ET
Eidos Therapeutics Presents Data from its Phase 1 Clinical Trial of AG10 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) announced the presentation of results from its Phase 1 clinical trial of AG10 during a poster session at the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA). The poster,...
Aug 23, 2018 08:00 am ET
Eidos Therapeutics Announces Publication of AG10 Molecular Design in Journal of Medicinal Chemistry
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced publication of the design and preclinical characterization of its lead product candidate, AG10, in the Journal of Medicinal Chemistry...
Aug 07, 2018 04:30 pm ET
Eidos Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today reported its financial results for...
Jun 22, 2018 04:05 pm ET
Eidos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, June 22, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced the closing of its initial public offering of 7,187,500 shares of common stock, including the exercise in full of the underwriters' option to purchase 937,500 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Eidos from the offering were approximately $122.2 million, bef
Jun 19, 2018 10:49 pm ET
Eidos Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO, June 19, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $17.00 per share. All of the shares are being offered by Eidos. The shares are expected to begin trading on the Nasdaq Global Select Market on June 20, 2018 under the ticker symbol "EIDX." The gross proceeds from the offering,

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.